Express Mail Label No.: EV392126555US

Pate of Deposit: January 14, 2005

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Wagle et al.

SERIAL NUMBER: 10/036,856

EXAMINER: Cybille Delacroix-Muirheid

Attorney Docket No.: 26448-507

Reg No. 50,572

FILING DATE: December 31, 2001

**ART UNIT: 1614** 

FOR: METHODS FOR TREATING GLAUCOMA II B

### Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

Response to November 15, 2004 Office Action (10 pages); and

Return Postcard.

Although the Applicants believe that no fees are due, the Commissioner is hereby authorized to charge any fees that may be due to Deposit Account No. 50-0311 (Ref. No. 26448-507). If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicant

c/o Mintz, Levin

Telephone: (617) 542 6000

Fax: (617) 542 2241 Customer No.: 30623

Dated: January 14, 2005

Express Mail Label No.: EV392126555US

Date of Deposit: January 14, 2005

Attorney Docket No.: 26448

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Wagle et al.

SERIAL NUMBER: 10/036,856

EXAMINER: Cybille Delacroix-Muirheid

FILING DATE: December 31, 2001

**ART UNIT: 1614** 

FOR: METHODS FOR TREATING GLAUCOMA II B

#### Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### AMENDMENT AND RESPONSE TO NOVEMBER 15, 2004 OFFICE ACTION

This paper is in response to the November 15, 2004 Office Action. A response is due on or before February 15, 2005. Applicants believe no fees are due. However, the Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 26448-507.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks** are shown starting on page 9 of this paper.